Chinese herbal medicines in the treatment of ulcerative colitis: a review.
Chinese herbal medicine formula
Clinical practice of Chinese medicine
Data mining
Literature review
Pattern identification
Ulcerative colitis
Journal
Chinese medicine
ISSN: 1749-8546
Titre abrégé: Chin Med
Pays: England
ID NLM: 101265109
Informations de publication
Date de publication:
04 Apr 2022
04 Apr 2022
Historique:
received:
10
11
2021
accepted:
13
03
2022
entrez:
5
4
2022
pubmed:
6
4
2022
medline:
6
4
2022
Statut:
epublish
Résumé
To investigate how the ulcerative colitis (UC) be treated with Chinese herbal medicines (CHM), using Chinese medicine (CM) pattern (zheng) identification, in the current clinical practice. A total of 7 electronic databases were systematically searched for UC clinical studies with CHM interventions (including single herbs and CHM formulas) published in English and Chinese from the date of their inception to November 25, 2020. Descriptive statistics were adopted to demonstrate the characteristics of study design, and to collate the commonly CM patterns of UC and frequently used CHM herbs and formulas. Further, IBM SPSS Modeler 18.0 and Cytoscape 3.7.1 software were used to analyze and visualize the associations between different categories of CHM and their zheng indications. A total of 2311 articles were included in this study, of which most (> 90%) were RCTs with CHM formulas. The most common zheng of UC was Large intestine dampness-heat, while the basic type of CM patten was Spleen deficiency. The most frequently used classical formula was Bai-Tou-Weng-Tang, followed by Shen-Ling-Bai-Zhu-San, and the commonly used proprietary CHM was Xi-Lei-San (enema). Sulfasalazine and Mesalazine are commonly used as concomitant western medicines. The most frequently used single medicinals were Huang Lian and Bai Zhu, which also identified as the core herbs for different CM patterns. This study examined the application of CHM interventions for UC and summarized their characteristics in clinical practice. These data indicated there were limited information about the safety assessment of CHM formulas and further RCTs including CM pattern(s) with strict design are necessary.
Identifiants
pubmed: 35379276
doi: 10.1186/s13020-022-00591-x
pii: 10.1186/s13020-022-00591-x
pmc: PMC8981751
doi:
Types de publication
Journal Article
Langues
eng
Pagination
43Subventions
Organisme : Health@InnoHK Initiative Fund of the Hong Kong Special Administrative Region Government
ID : ITC RC/IHK/4/7
Informations de copyright
© 2022. The Author(s).
Références
J Crohns Colitis. 2015 Jan;9(1):86-106
pubmed: 25518050
Mayo Clin Proc. 2014 Nov;89(11):1553-63
pubmed: 25199861
Paediatr Drugs. 2014 Jun;16(3):189-98
pubmed: 24723200
Medicine (Baltimore). 2017 Apr;96(16):e6651
pubmed: 28422869
BMC Complement Med Ther. 2021 Sep 13;21(1):228
pubmed: 34517855
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
Semin Pediatr Surg. 2007 Aug;16(3):146-53
pubmed: 17602969
Ann Intern Med. 2017 Jun 27;167(2):112-121
pubmed: 28654980
PLoS One. 2013;8(3):e59241
pubmed: 23555003
Am J Gastroenterol. 2012 Aug;107(8):1228-35
pubmed: 22613902
Inflamm Bowel Dis. 2016 Jun;22(6):1412-7
pubmed: 27120570
J Dig Dis. 2017 Feb;18(2):92-98
pubmed: 28102560
Ther Adv Chronic Dis. 2018 Feb;9(2):65-72
pubmed: 29387331
Chin Med. 2015 Oct 13;10:29
pubmed: 26464580
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
Nature. 2018 Nov;563(7730):S33
pubmed: 30405234
Aliment Pharmacol Ther. 2013 Oct;38(8):854-63
pubmed: 23981095
BMC Complement Med Ther. 2020 Oct 14;20(1):309
pubmed: 33054760
Am J Gastroenterol. 2010 Mar;105(3):501-23; quiz 524
pubmed: 20068560
Aliment Pharmacol Ther. 2010 Apr;31(7):693-707
pubmed: 20064142
Nature. 2018 Sep;561(7724):448-450
pubmed: 30258149
Aliment Pharmacol Ther. 2003 Jul 15;18(2):191-8
pubmed: 12869079
Clin Rev Allergy Immunol. 2013 Jun;44(3):274-83
pubmed: 22669756